Dosing lamivudine or emtricitabine in renal impairment: new data confirm it's time for updated guidance!

Affiliations

¹ Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
² Chelsea and Westminster Hospital NHS Foundation Trust, LSHTM, London, UK.

Comment

Brian R Wood et al. AIDS. 2021.

. 2021 Jul 1;35(8):1305-1307.

doi: 10.1097/QAD.0000000000002903.

¹ Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
² Chelsea and Westminster Hospital NHS Foundation Trust, LSHTM, London, UK.

No abstract available

Comment on

To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment.
Mounzer K, Brunet L, Wyatt CM, Fusco JS, Vannappagari V, Tenorio AR, Shaefer MS, Ragone L, Hsu RK, Fusco GP. Mounzer K, et al. AIDS. 2021 Jul 1;35(8):1201-1208. doi: 10.1097/QAD.0000000000002871. AIDS. 2021. PMID: 33710017

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available at: http://www.clinicalinfo.hiv.gov/en/guidelines . [Accessed 15 March 2021]. Appendix B, Table 10, page P–16. Last updated 18 December 2019.
1. European AIDS Clinical Society Guidelines, Version 10.1, October 2020. Available at: eacssociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. [Accessed 15 March 2021]. Page 67.
1. Lamivudine (Epivir). Package insert. ViiV Healthcare; 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_0205... . [Accessed 15 March 2021].
1. Bouazza N, Treluyer JM, Ghosn J, Hirt D, Benaboud S, Foisac F, et al. Evaluation of effect of impaired renal function on lamivudine pharmacokinetics . Br J Clin Pharmacol 2014; 78:847–854.
1. Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction . Antimicrob Agents Chemother 1996; 40:1514–1519.